ClinicalTrials.gg
CompletedNCT03571516Updated May 11, 2021Results posted

Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome

A Phase 3 interventional study of Teduglutide and Standard Medical Therapy in Short Bowel Syndrome, sponsored by Shire. Completed at 8 sites in 4 countries. Open to participants aged 4 Months to 12 Months. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
4 Months to 12 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
15th of 20
10 · median 20
Started
2018
with 3 others
Phase 3
16 of 20
none open now
Registered
14th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 15th largest by enrollment, is one of 4 that started in 2018, is one of 16 in phase 3, and was the 14th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 4 Months to 12 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, efficacy/pharmacodynamics (PD) and pharmacokinetics (PK) of teduglutide treatment in infants with short bowel syndrome (SBS) dependent on parenteral (PN) support.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

Keywords

  • Short bowel syndrome
  • Teduglutide
04

Who can participate

Ages eligible
4 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • by the parent or legal guardian.
  • Male or female infant 4 to 12 months corrected gestational age at screening.
  • Weight at least 5 kilogram (kg) and weight-for-length Z-score greater than -2 at screening and baseline.
  • Short bowel syndrome with dependence on parenteral support to provide at least 50% of fluid or caloric needs.
  • Stable PN requirements for at least 1 month prior to screening, defined as a less than or equal to (\<=) 10% change in the weight-normalized PN total fluid and caloric intake, despite attempts to wean PN, not withstanding transient instability for events such as sepsis or interruption of central venous access.
  • Parent or legal guardian understands and is willing and able to fully adhere to study requirements as defined in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with teduglutide.
  • Intestinal malabsorption due to a genetic condition, such as cystic fibrosis, microvillus inclusion disease, etc.
  • Severe, known dysmotility syndrome, such as pseudo-obstruction or persistent, severe, active gastroschisis-related dysmotility, that is the primary contributing factor to feeding intolerance and inability to reduce PN support, prior to screening. Dysmotility is defined as severe if it is expected to limit the advancement of enteral feeding.
  • Inability to advance oral or enteral feeding due to lack of access to the gut, such as oral aversion in the absence of a feeding tube.
  • Intestinal obstruction or intestinal stenosis.
  • Major gastrointestinal surgical intervention, such as serial transverse enteroplasty or major intestinal resection or anastomosis, within 3 months prior to screening or planned during the study period.
  • Unstable cardiac disease.
  • Renal dysfunction, defined as estimated less than (\<) 50 milliliter per minute (mL/min) per 1.73 square meter (m\^2).
  • Biliary obstruction, stenosis, or malformation.
  • Clinically significant pancreatic disease.
  • Severe hepatic dysfunction or portal hypertension, defined by at least 2 of the following parameters:

    1. (INR) greater than (>) 1.5 not corrected with PN vitamin K
    2. count \<100×10\^3/ microliter (mcL) due to portal hypertension
    3. Presence of clinically significant gastric or esophageal varices
    4. Documented cirrhosis
  • Persistent cholestasis defined as conjugated >4 milligram per deciliter (mg/dL) (>68 micromoles per liter [mcmol/L]) over a 2 week period.
  • More than 3 serious complications of intestinal failure (example [e.g.], catheter-associated bloodstream infections, interruption of nutrition due to feeding intolerance, catheter-associated thrombosis, severe fluid or electrolyte disturbances) within 1 month prior to or during screening.
  • A history of cancer or a known cancer predisposition syndrome, such as juvenile polyposis or Beckwith-Wiedemann syndrome, or first degree relative with early onset of gastrointestinal cancer (including hepatobiliary and pancreatic cancers).
  • Concurrent treatment with glucagon-like peptide-1 (GLP-1); glucagon-like peptide-2 (GLP-2); insulin-like growth factor-1 (IGF-1); growth hormone, somatostatin, or analogs of these hormones; or glutamine.
  • Participation in a clinical study using an experimental drug within 3 months or 5.5 half-lives of the experimental drug, whichever is longer.
  • Known or suspected intolerance or to the product, closely-related compounds, or any of the stated ingredients.
  • Any condition, disease, illness, or circumstance that, in the investigator's opinion, puts the participant at any undue risk, prevents completion of the study, or interferes with analysis of the study results.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Teduglutide

    Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.

    Drug: Teduglutide · Other: Standard Medical Therapy · Device: Syringe · Device: Needle

  • Other
    Standard of Care (SOC)

    Participants will receive standard medical therapy for 24 weeks.

    Other: Standard Medical Therapy · Device: Syringe · Device: Needle

Interventions

  • SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.

  • OtherStandard Medical Therapy

    Standard medical therapy will be administered for 24 weeks.

  • DeviceSyringe

    Teduglutide will be administered using syringe (510k number: K980987).

  • DeviceNeedle

    Teduglutide will be administered using needle (510k number: K021475).

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

    Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

Secondary outcomes

  1. Plasma Concentration of Teduglutide at Nominal Time Points (Baseline at Pre-dose, and 1 Hour and 4 Hours Post-dose; 2 Hours Post-dose at Week 7)

    Mean plasma concentration of teduglutide was reported.

    Time frame: Baseline: Pre-dose,1, 4 hours post-dose, and 2 hours post-dose at Week 7

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product.

    Time frame: From start of study treatment up to end of study (EOS) (up to Week 28)

  3. Change From Baseline in Body Weight Z-score at Week 24

    Body weight was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight Z-score at Week 24 was reported.

    Time frame: Baseline, Week 24

  4. Change From Baseline in Length Z-Score at Week 24

    Length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in length Z-score at Week 24 was reported.

    Time frame: Baseline, Week 24

  5. Change From Baseline in Head Circumference Z-Score at Week 24

    Head circumference was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference Z-score at Week 24 was reported.

    Time frame: Baseline, Week 24

  6. Change From Baseline in Weight-for-Length Z-Score at Week 24

    Weight-for-length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in weight-for-length Z-score at Week 24 was reported.

    Time frame: Baseline, Week 24

  7. Change From Baseline in Average Total Urine Output at Week 24

    Average total urine output was recorded over a 48-hour period of nutritional stability at Week 24 was reported. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.

    Time frame: Baseline, Week 24

  8. Change From Baseline in Fecal Output at Week 24

    Change from baseline in the fecal output (average number of stools per day) at Week 24 was reported.

    Time frame: Baseline, Week 24

  9. Number of Participants With Positive Specific Antibodies to Teduglutide

    Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.

    Time frame: Baseline, EOS (up to week 28)

  10. Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

    Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  11. Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at Week 24

    Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at Week 24 were reported.

    Time frame: Week 24

  12. Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at End of Study (EOS)

    Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at EOS (up to Week 28) were reported.

    Time frame: EOS (up to Week 28)

  13. Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  14. Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

    Percent change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  15. Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).

    Time frame: Baseline, EOT/ET (up to Week 24)

  16. Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

    Percent change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  17. Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  18. Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)

    Percent change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  19. Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

    Change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  20. Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

    Percent change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  21. Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)

    Number of participants who achieved at least 20% increase from baseline in weight-normalized EN volume at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

  22. Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

    Number of participants who achieved at least 20% increase from baseline in weight-normalized EN caloric intake at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

    Time frame: Baseline, EOT/ET (up to Week 24)

07

Results

Posted Apr 8, 2021

Participant flow

The study was conducted at Finland and United Kingdom between 31 August 2018 (first participant first visit) and 24 September 2020 (last participant last visit).

Participant flow — Overall Study
MilestoneTeduglutide (TED)Standard of Care (SOC)
Started55
Completed44
Not completed11
Withdrew: Severe diarrhea10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
ParticipantsTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET31
Prescribed Data: EOT/ET33
SecondaryPlasma Concentration of Teduglutide at Nominal Time Points (Baseline at Pre-dose, and 1 Hour and 4 Hours Post-dose; 2 Hours Post-dose at Week 7)

Mean plasma concentration of teduglutide was reported.

Time frame:
Baseline: Pre-dose,1, 4 hours post-dose, and 2 hours post-dose at Week 7
Reported as:
Median · Nanogram per milliliter (ng/mL)
Plasma Concentration of Teduglutide at Nominal Time Points (Baseline at Pre-dose, and 1 Hour and 4 Hours Post-dose; 2 Hours Post-dose at Week 7)
Nanogram per milliliter (ng/mL)Teduglutide (TED)
Baseline: At Pre-dose0.00 (0.00 to 0.00)
Baseline: At 1 hour16.300 (7.25 to 25.70)
Baseline: At 4 hours8.385 (3.86 to 22.5)
Week 7: At 2 hours16.950 (14.80 to 19.10)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of investigational product.

Time frame:
From start of study treatment up to end of study (EOS) (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTeduglutide (TED)Standard of Care (SOC)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)55
SecondaryChange From Baseline in Body Weight Z-score at Week 24

Body weight was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight Z-score at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Z-score
Change From Baseline in Body Weight Z-score at Week 24
Z-scoreTeduglutide (TED)Standard of Care (SOC)
Change From Baseline in Body Weight Z-score at Week 24-0.408 ± 0.377-0.289 ± 0.278
SecondaryChange From Baseline in Length Z-Score at Week 24

Length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in length Z-score at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Z-Score
Change From Baseline in Length Z-Score at Week 24
Z-ScoreTeduglutide (TED)Standard of Care (SOC)
Change From Baseline in Length Z-Score at Week 24-0.274 ± 1.258-0.422 ± 0.384
SecondaryChange From Baseline in Head Circumference Z-Score at Week 24

Head circumference was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in head circumference Z-score at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Z-Score
Change From Baseline in Head Circumference Z-Score at Week 24
Z-ScoreTeduglutide (TED)Standard of Care (SOC)
Change From Baseline in Head Circumference Z-Score at Week 24-0.544 ± 0.446-0.167 ± 0.690
SecondaryChange From Baseline in Weight-for-Length Z-Score at Week 24

Weight-for-length was measured using Z-score. Z-score was calculated as (observed value - median value of the reference population)/standard deviation value of reference population. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in weight-for-length Z-score at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Z-Score
Change From Baseline in Weight-for-Length Z-Score at Week 24
Z-ScoreTeduglutide (TED)Standard of Care (SOC)
Change From Baseline in Weight-for-Length Z-Score at Week 24-0.447 ± 1.042-0.058 ± 0.992
SecondaryChange From Baseline in Average Total Urine Output at Week 24

Average total urine output was recorded over a 48-hour period of nutritional stability at Week 24 was reported. Here, milliliter per kilogram per day is abbreviated as mL/kg/day.

Time frame:
Baseline, Week 24
Reported as:
Mean · mL/kg/day
Change From Baseline in Average Total Urine Output at Week 24
mL/kg/dayTeduglutide (TED)Standard of Care (SOC)
Change From Baseline in Average Total Urine Output at Week 24-0.61 ± 14.54810.25 ± 17.383
SecondaryChange From Baseline in Fecal Output at Week 24

Change from baseline in the fecal output (average number of stools per day) at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · Average number of stools per day
Change From Baseline in Fecal Output at Week 24
Average number of stools per dayTeduglutide (TED)Standard of Care (SOC)
Change From Baseline in Fecal Output at Week 24-3.33 ± 3.5471.67 ± 1.756
SecondaryNumber of Participants With Positive Specific Antibodies to Teduglutide

Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.

Time frame:
Baseline, EOS (up to week 28)
Reported as:
Count of participants · Participants
Number of Participants With Positive Specific Antibodies to Teduglutide
ParticipantsTeduglutide (TED)
Number of Participants With Positive Specific Antibodies to Teduglutide0
SecondaryNumber of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

Number of participants who achieved at least 20% reduction from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
ParticipantsTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET31
Prescribed Data: EOT/ET33
SecondaryNumber of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at Week 24

Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at Week 24 were reported.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at Week 24
ParticipantsTeduglutide (TED)Standard of Care (SOC)
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at Week 2400
SecondaryNumber of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at End of Study (EOS)

Number of participants who achieved 100% reduction in complete weaning off (enteral autonomy) PS volume at EOS (up to Week 28) were reported.

Time frame:
EOS (up to Week 28)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at End of Study (EOS)
ParticipantsTeduglutide (TED)Standard of Care (SOC)
Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning Off (Enteral Autonomy) Parenteral Support (PS) Volume at End of Study (EOS)00
SecondaryChange From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

Change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · mL/kg/day
Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
mL/kg/dayTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET-21.54 ± 28.909-9.51 ± 7.497
Prescribed Data: EOT/ET-22.90 ± 26.940-14.90 ± 12.323
SecondaryPercent Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)

Percent change from baseline in weight-normalized PS volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Volume at End of Treatment/Early Termination (EOT/ET)
Percent changeTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET-24.77 ± 34.723-16.75 ± 16.392
Prescribed Data: EOT/ET-27.28 ± 33.518-22.39 ± 17.198
SecondaryChange From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

Change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · kcal/kg/day
Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
kcal/kg/dayTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET-16.14 ± 17.547-6.10 ± 10.386
Prescribed Data: EOT/ET-15.31 ± 17.839-20.40 ± 21.024
SecondaryPercent Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

Percent change from baseline in weight-normalized PS caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Weight-normalized Parenteral Support (PS) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Percent changeTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET-27.00 ± 29.473-13.68 ± 21.873
Prescribed Data: EOT/ET-27.81 ± 30.777-38.86 ± 39.893
SecondaryChange From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)

Change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · mL/kg/day
Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)
mL/kg/dayTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET16.14 ± 18.683-15.25 ± 31.496
Prescribed Data: EOT/ET-1.28 ± 2.5632.27 ± 22.232
SecondaryPercent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)

Percent change from baseline in weight-normalized EN volume at EOT/ET (up to Week 24) was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)
Percent changeTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET273.20 ± 246.784-44.25 ± 78.847
Prescribed Data: EOT/ET-16.40 ± NA14.80 ± 69.834
SecondaryChange From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

Change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · kcal/kg/day
Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
kcal/kg/dayTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET9.08 ± 10.662-9.38 ± 21.402
Prescribed Data: EOT/ET-1.15 ± 2.3063.11 ± 16.285
SecondaryPercent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

Percent change from baseline in weight-normalized EN caloric intake at EOT/ET (up to Week 24) were reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Mean · Percent change
Percent Change From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
Percent changeTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET207.06 ± 153.159-44.25 ± 78.847
Prescribed Data: EOT/ET-16.40 ± NA24.18 ± 78.115
SecondaryNumber of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)

Number of participants who achieved at least 20% increase from baseline in weight-normalized EN volume at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Volume at End of Treatment/Early Termination (EOT/ET)
ParticipantsTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET20
Prescribed Data: EOT/ET02
SecondaryNumber of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)

Number of participants who achieved at least 20% increase from baseline in weight-normalized EN caloric intake at EOT/ET was reported. EOT/ET was defined as the last available visit after the date of first dose (or randomization in standard of care treatment group) during the 24-week treatment period.

Time frame:
Baseline, EOT/ET (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20 Percent (%) Increase From Baseline in Weight-normalized Enteral Nutrition (EN) Caloric Intake at End of Treatment/Early Termination (EOT/ET)
ParticipantsTeduglutide (TED)Standard of Care (SOC)
Diary Data: EOT/ET20
Prescribed Data: EOT/ET02

Adverse events

Collected over From start of study treatment up to end of study (EOS) (up to Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Teduglutide (TED)0/5 (0%)4/5 (80%)5/5 (100%)
Standard of Care (SOC)0/5 (0%)3/5 (60%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventTeduglutide (TED)Standard of Care (SOC)
Device related infectionInfections and infestations0/52/5
PyrexiaGeneral disorders1/50/5
Immunisation reactionImmune system disorders1/50/5
Transaminases increasedInvestigations0/51/5
Metabolic acidosisMetabolism and nutrition disorders0/51/5
AtaxiaNervous system disorders0/51/5
Device breakageProduct Issues1/50/5
Device leakageProduct Issues1/50/5
Device occlusionProduct Issues0/51/5
Most frequent other events
Showing 10 of 46
Most frequent other events
EventTeduglutide (TED)Standard of Care (SOC)
VomitingGastrointestinal disorders3/51/5
DiarrhoeaGastrointestinal disorders2/50/5
Frequent bowel movementsGastrointestinal disorders2/50/5
TeethingGastrointestinal disorders0/52/5
NasopharyngitisInfections and infestations2/50/5
Upper respiratory tract infectionInfections and infestations1/52/5
AnaemiaBlood and lymphatic system disorders1/50/5
Iron deficiency anaemiaBlood and lymphatic system disorders1/50/5
Abdominal discomfortGastrointestinal disorders1/50/5
Abdominal distensionGastrointestinal disorders1/50/5

Baseline characteristics

Safety set consisted of all participants who met the following criteria: Teduglutide treatment arm: participants who received at least 1 dose of teduglutide and had undergone at least 1 post baseline safety assessment; Standard of care treatment arm: participants who had undergone at least 1 post baseline safety assessment.

Age, Continuous
Age, Continuous(Months)Teduglutide (TED)Standard of Care (SOC)Total
Mean8.5 ± 3.098.3 ± 2.658.4 ± 2.71
Sex: Female, Male
Sex: Female, Male(Participants)Teduglutide (TED)Standard of Care (SOC)Total
Female123
Male437
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Teduglutide (TED)Standard of Care (SOC)Total
Hispanic or Latino000
Not Hispanic or Latino5510
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Teduglutide (TED)Standard of Care (SOC)Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White448
More than one race000
Unknown or Not Reported000
08

Study locations

8 sites
  • Helsingin yliopistollinen keskussairaala
    Helsinki, 00290, Finland
  • Groupe Hospitalier Pellegrin - Hôpital des Enfants
    Bordeaux, Gironde 33000, France
  • Hopital Jeanne de Flandre - CHRU Lille
    Lille, Nord 59037, France
  • Ospedale Pediatrico Bambino Gesù
    Roma, 00165, Italy
  • Great Ormond Street Hospital for Children
    London, Greater London WC1N 3JH, United Kingdom
  • Royal Manchester Children's Hospital
    Manchester, Greater Manchester M13 9WL, United Kingdom
  • Alder Hey Childrens Hospital
    Liverpool, Merseyside L12 2AP, United Kingdom
  • Birmingham Children's Hospital
    Birmingham, West Midlands B4 6NH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Sep 2020, 24 months.

Results were first posted in Apr 2021, 6 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 24 months is below that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2018
First posted
Jun 27, 2018
StartActual
Aug 31, 2018
Primary completionActual
Sep 24, 2020
CompletionActual
Sep 24, 2020
Results first posted
Apr 8, 2021
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03571516
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
Aug 31, 2018
Primary completion
Sep 24, 2020
Completion
Sep 24, 2020
Results posted
Apr 8, 2021
Last update
May 11, 2021

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion